Old malaria drug may help lung cancer treatment last longer
NCT ID NCT00977470
Summary
This study is testing whether adding the drug hydroxychloroquine (used for malaria and arthritis) to the cancer drug erlotinib helps control advanced non-small cell lung cancer for a longer period. It involves 76 adults with a specific genetic mutation in their cancer who have not yet received treatment for their advanced disease. Participants are randomly assigned to receive either erlotinib alone or the combination, to see if the combination can delay the cancer's ability to become resistant to treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Stanford Cancer Institute
Stanford, California, 94305, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
Yale Cancer Center
New Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.